GRF Stock Overview
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.26 |
| 52 Week High | €15.51 |
| 52 Week Low | €6.58 |
| Beta | 0.68 |
| 1 Month Change | 4.35% |
| 3 Month Change | -12.17% |
| 1 Year Change | -9.57% |
| 3 Year Change | -64.09% |
| 5 Year Change | -66.56% |
| Change since IPO | -65.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| GRF | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | -5.0% | -0.4% | 1.5% |
| 1Y | -9.6% | -12.9% | 3.5% |
Return vs Industry: GRF exceeded the Austrian Biotechs industry which returned -12.9% over the past year.
Return vs Market: GRF underperformed the Austrian Market which returned 3.5% over the past year.
Price Volatility
| GRF volatility | |
|---|---|
| GRF Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.6% |
Stable Share Price: GRF's share price has been volatile over the past 3 months.
Volatility Over Time: GRF's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,744 | Nacho Abia | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
Grifols, S.A. Fundamentals Summary
| GRF fundamental statistics | |
|---|---|
| Market cap | €5.22b |
| Earnings (TTM) | €59.32m |
| Revenue (TTM) | €6.59b |
99.1x
P/E Ratio0.9x
P/S RatioIs GRF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRF income statement (TTM) | |
|---|---|
| Revenue | €6.59b |
| Cost of Revenue | €4.10b |
| Gross Profit | €2.49b |
| Other Expenses | €2.44b |
| Earnings | €59.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 0.087 |
| Gross Margin | 37.84% |
| Net Profit Margin | 0.90% |
| Debt/Equity Ratio | 119.6% |
How did GRF perform over the long term?
See historical performance and comparison